Intrinsic and Acquired Drug Resistance in Malignant Tumors

Abstract

Drug resistance is the major reason for failure in cancer chemotherapy. Resistance may be either pre-existent (intrinsic resistance), or induced by drugs (acquired resistance), So far, no strategy has been found to overcome resistance, which is based on highly complex and individually variable biological mechanisms. In present clinical practice, drug resistance can only be recognized during treatment, after long lag times. Thus diagnostic tests are re quired, indicating resistance at an earlier stage, in order to avoid unnecessary medication, frequently associated with toxic side-effects. A number of new anti-cancer drugs are now available. In contrast to the unspecifically acting cytostatic chemotherapy, these compounds have targeted actions. However, as recent studies have shown, resistances and severe side-effects can also be found with targeted drugs. With the increasing number of new treatment regimens, the early diagnosis of resistance will optimize therapy, and indeed will be indispensable for individual cancer therapy. The resistance assays available for use in clinical practice should be integrated into cancer therapy. Research into this neglected area needs to be intensified.

Short Communication: Coral reef lifeform variation around power plant activity: Case study on coastal area of Paiton Power Plant, East Java, Indonesia

“…Treatments of cervical cancer usually consist of chemotherapy, radiotherapy and surgery, but these treatments still have the side effect to the patients. Lippert et al (2008) state most of the drugs used for anti-cancer are expensive, highly toxic and also having side effect such as resistance mechanism. Therefore, many researchers conduct the research on used medicinal plants to overcome the cervical cancer.…”

miR‑30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy

“…However, at present, intrinsic or acquired multidrug resistance (MDR) represents a major obstacle for successful cancer chemotherapy (4). The mechanism underlying MDR is complex due to interactions between various factors, including drug efflux, the alteration of drug targets, DNA damage repair, cell proliferation and apoptosis, and cell cycle changes (5)(6)(7).…”

Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells

“…By binding to the covalent complex formed by Top1 and DNA, CPTs prevent the re-ligation of DNA, which leads to persistent DNA breaks, subsequently inducing cell apoptosis [2] . Clinical data show that the efficiency of CPTs varies between patients, and the resistance mechanism remains to be determined [3] . Previous studies indicated that the resistant phenotype may be the result of inadequate drug accumulation in cancer cells, alterations in the target Top1 and alterations in cellular drug responses including DNA repair and apoptosis [4][5][6] .…”